Retirement Systems of Alabama Boosts Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Retirement Systems of Alabama raised its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 128.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 193,101 shares of the medical equipment provider’s stock after buying an additional 108,759 shares during the quarter. Retirement Systems of Alabama’s holdings in Lantheus were worth $17,275,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in LNTH. Geode Capital Management LLC increased its position in Lantheus by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after purchasing an additional 32,551 shares during the last quarter. Moloney Securities Asset Management LLC purchased a new stake in shares of Lantheus during the 3rd quarter valued at about $1,066,000. Massachusetts Financial Services Co. MA bought a new position in shares of Lantheus in the 3rd quarter valued at about $25,955,000. Van ECK Associates Corp grew its position in Lantheus by 58.6% in the third quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock worth $6,469,000 after acquiring an additional 21,604 shares in the last quarter. Finally, Empirical Asset Management LLC purchased a new stake in Lantheus during the fourth quarter valued at approximately $323,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $90.90 on Friday. Lantheus Holdings, Inc. has a 52-week low of $53.47 and a 52-week high of $126.89. The firm has a market capitalization of $6.32 billion, a price-to-earnings ratio of 15.12 and a beta of 0.44. The stock has a 50 day moving average price of $92.09 and a 200 day moving average price of $99.04.

Insiders Place Their Bets

In related news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Truist Financial restated a “buy” rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. The Goldman Sachs Group began coverage on Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price for the company. Finally, JMP Securities reiterated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $131.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.